Skip to main content
Premium Trial:

Request an Annual Quote

Silence Inks Delivery Tech Evaluation Deal with Mireven


Silence Therapeutics this week announced that it has struck a deal under which its delivery technologies will be evaluated by Australian microRNA drug developer Mireven for use with its therapeutic candidates.

Silence will formulate a mimic of miR-7 using its three lipid-based delivery technologies: AtuPlex, which is used in the company's phase I siRNA cancer drug Atu-027; DACC, which selectively targets the lung endothelium; and DBTC, which targets liver cells.

Silence will then test the mimics in vitro and in vivo, and is receiving an undisclosed fee.

Additional terms were not disclosed.

The arrangement with Mireven marks the fourth time a miRNA drug company has signed on to try out Silence's delivery technologies. In January, it inked such a deal with Miragen Therapeutics (GSN 1/12/2012); in late 2011, it forged a similar arrangement with Mirna Therapeutics (GSN 10/27/2011); and about a year ago it began working with InteRNA Technologies (GSN 9/15/2011).